|
EXOSC9 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.1398995342945E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.064599961635E-09 |
| Normal-vs-Stage2 |
3.26029980790565E-10 |
| Normal-vs-Stage3 |
3.17620000300778E-08 |
| Normal-vs-Stage4 |
2.14319995084367E-09 |
| Stage1-vs-Stage2 |
1.377710E-02 |
| Stage1-vs-Stage3 |
6.191400E-01 |
| Stage1-vs-Stage4 |
2.207400E-01 |
| Stage2-vs-Stage3 |
6.101900E-02 |
| Stage2-vs-Stage4 |
1.728620E-01 |
| Stage3-vs-Stage4 |
5.311800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.72779584978389E-11 |
| Normal-vs-AfricanAmerican |
1.677780E-02 |
| Normal-vs-Asian |
3.767100E-04 |
| Caucasian-vs-AfricanAmerican |
4.536000E-02 |
| Caucasian-vs-Asian |
6.710400E-02 |
| AfricanAmerican-vs-Asian |
5.898200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.24010032745525E-10 |
| Normal-vs-Female |
4.06629951932302E-10 |
| Male-vs-Female |
3.529200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
9.13700000104711E-08 |
| Normal-vs-Age(41-60Yrs) |
1.80899739632423E-11 |
| Normal-vs-Age(61-80Yrs) |
2.75339973043742E-10 |
| Normal-vs-Age(81-100Yrs) |
1.183420E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.510000E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.219500E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.956800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.846600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.306200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.127980E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.375410E-01 |
| Classical-VS-Follicular |
3.23540000002343E-06 |
| Classical-VS-Other |
1.022750E-01 |
| Classical-VS-Normal |
3.87130000278901E-08 |
| Tall-VS-Follicular |
1.011390E-01 |
| Tall-VS-Other |
4.201800E-01 |
| Tall-VS-Normal |
3.65660000001267E-06 |
| Follicular-VS-Other |
8.278000E-01 |
| Follicular-VS-Normal |
1.40589762054333E-11 |
| Other-VS-Normal |
7.611100E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.70830066443295E-11 |
| Normal-vs-N1 |
1.56344999999725E-05 |
| N0-vs-N1 |
4.475900E-02 |
|
|
